WHAT A SURPRISE!

PEDIATRICS ◽  
1994 ◽  
Vol 94 (5) ◽  
pp. 747-747
Keyword(s):  
Research And Development ◽  
Senate Committee ◽  
Drug Companies

Drug companies ... claim that they price drugs as they do to compensate for huge investments in research and development. But the Senate Committee on Aging said in a report that more money is spent on marketing drugs than developing them.

AIDS Drugs & the Pharmaceutical Industry: A Need For Reform

1991 ◽  
Vol 17 (4) ◽  
pp. 363-410
Author(s):  
Mary T. Griffin
Keyword(s):  
Pharmaceutical Industry ◽  
Research And Development ◽  
Drug Approval ◽  
Hiv And Aids ◽  
Price Regulation ◽  
Drug Industry ◽  
Drug Companies ◽  
Aids Drugs

AbstractThe pharmaceutical industry has long enjoyed substantial profits despite increased requirements for drug approval and various attempts to regulate the industry. Drug companies have avoided effective regulation by blaming high prices on the costs of research and development. The search for drugs effective in combatting HIV and AIDS related illnesses has provided a stark background on which to view the actions and justifications of drug companies. Despite increased cooperation between government and the drug industry and expedited approval of several useful drugs, these drugs are still prohibitively expensive. This Article explores the history and economics of the drug industry and proposes a system of national price regulation for all drugs.

Commentaries & Analyses — Strategic Balancing Of Patent And FDA Approval Processes To Maximize Market Exclusivity

2003 ◽  
Vol 07 (16) ◽  
pp. 997-1005
Author(s):  
DENNIS S. FERNANDEZ ◽  
JAMES T. HUIE
Keyword(s):  
Research And Development ◽  
Drug Administration ◽  
Generic Drug ◽  
Market Entry ◽  
Market Exclusivity ◽  
Federal Drug Administration ◽  
Biotech Company ◽  
Company Value ◽  
Drug Companies ◽  
Fda Approval

The patentability of products is essential in the biotechnology field, for limited market exclusivity compensates biotech companies' investments in research and development. The biotechnology field also uniquely faces Federal Drug Administration (FDA) approval, which includes considerable additional expense and time issues a biotech company must address. Although balancing the patent and FDA approval processes may be complex, various strategies of patent extension, of accelerating approval processes, and of prolonging generic drug companies' market entry can yield higher profit returns and maximize value company value.

scholarly journals Drugs Company Profits In The United States: Are They Excessive? Evidence From Public Administration Perspectives

2011 ◽  
Vol 4 (2) ◽  
Author(s):  
Michael O. Adams ◽  
Gbolahan S. Osho
Keyword(s):  
United States ◽  
Research And Development ◽  
Prescription Drugs ◽  
Generic Drugs ◽  
Developed Countries ◽  
The United States ◽  
Drug Industry ◽  
Drug Companies ◽  
Cost Of Drugs ◽  
The Cost

Historically, the drug industry has been one of the most profitable in the United States of America and has been attributed to the relatively high cost of drugs compared to other developed countries. The call on drug companies to reduce the costs has increased tremendously with the industry strongly resisting, claiming costs are justified to support research and development of newer and better drugs. This debate is currently ongoing in the legislature with strong lobbying from both sides of the divide.  Hence, the main objective of this research is to determine the reasons for the high cost of prescription drugs in the United States compared to other countries and suggest ways to make drugs more affordable. The solution to the problem will most likely come from a compromise by both sides involving government funded research and production of generic drugs by companies. This would bring down the cost of drugs while ensuring continuation of research and development and guarantee reasonable profits for the drug industry.

Sign in / Sign up

Export Citation Format

Share Document